Akari Therapeutics Plc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation United Kingdom
Business Address 401 EAST JACKSON STREET, TAMPA, FL, 33602
Mailing Address 401 EAST JACKSON STREET, TAMPA, FL, 33602
Phone (929) 274-7510
Fiscal Year End 1231
EIN 981034922
Financial Overview
FY2024
-$10.01M
Net Income
$28.33M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | February 2, 2026 | View on SEC |
| S-1 IPO registration statement | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 8-K Current report of material events | December 17, 2025 | View on SEC |
Material Events
8-K Strategy Change December 16, 2025
High Impact
- Akari Therapeutics shareholders approved a 1-for-20,000 reverse stock split.
- Shareholders authorized the company's board to issue new shares until June 2030 for future capital raising.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.